WILMINGTON, Del., June 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: 42 nd Annual Goldman Sachs Global Healthcare
- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 - - Dose Escalation Ongoing in Phase 1 Trial of Oral
WILMINGTON, Del., May 05, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the BofA Securities 2021 Virtual Health
– Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set to Initiate Early in the Second Quarter – – Clinical Data Readouts Expected in 2H21 for Lead PRMT5 Inhibitors PRT543 and PRT811 – – Phase 1 Dose-Escalation Study of Oral PRT1419 Ongoing – – Preclinical
WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences:
WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stock and 291,666
WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its upsized public offering of 2,208,334 shares of its
WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced a public offering of 1,750,000 shares of its common stock pursuant to a registration
- Completed I nitial P ublic O ffering of C ommon S tock, R aising G ross P roceeds of ~$ 181.9M - - Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 Trial of PRT811 - - Durable Complete Response Ongoing in HRD+ High Grade Serous Ovarian Cancer Patient in Phase 1 Trial of
WILMINGTON, Del., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the first patient has been dosed in its first-in-human Phase 1 open-label, multicenter, dose-escalation study of PRT1419 in
